Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Blood (2022) 140 (Supplement 1): 6345–6347.

https://doi.org/10.1182/blood-2022-162159

Published: 2022

Journal Articles

Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain

Josep-Maria Ribera, Olga Garcia, Pau Montesinos, Rebeca Rodríguez-Veiga, María García-Fortes, Abelardo Barez Garcia, Itziar Oiartzabal, Jose A Gonzalez-Campos, Jose Angel Mendez Sanchez, Maite Zudaire, Lucia Villalon, Oriana López-Godino, Cristina Gil, Ana Vicent, Raquel Saldaña, Marta Valero, Anna Torrent, Jesus Maria Hernández-Rivas

Blood (2021) 138 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2021-148368

Published: 2021

Journal Articles

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Josep-Maria Ribera, Olga Garcia, Jordi Ribera, Pau Montesinos, Isabel Cano, Pilar Martínez, Jordi Esteve, Daniel Esteban, María García-Fortes, Natalia Alonso, José González-Campos, Arancha Bermúdez, Anna Torrent, Eulàlia Genescà, Santiago Mercadal, Joaquín Martínez-López, Ramon Garcia-Sanz

Blood (2021) 138 (Supplement 1): 1230.

https://doi.org/10.1182/blood-2021-148310

Published: 2021

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Josep-Maria Ribera, Olga García, Pau Montesinos, MD PhD, Pilar Martinez, MD, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, MD, Anna Torrent, Joaquin Martinez-Lopez, MD, Santiago Mercadal, MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137489

Published: 2020

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Josep-Maria Ribera, MD PhD, Olga García, Pilar Martinez, MD, Pau Montesinos Fernandez, MD PhD, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, Susana Vives, MD, Mar Tormo, MD PhD, Jesús María Hernández-Rivas, MD PhD, Joaquin Martinez-Lopez, MD PhD, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 3874.

https://doi.org/10.1182/blood-2019-125558

Published: 2019

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

Journal Articles

New Prognosis Score Including Absolute Lymphocytes/Monocytes Ratio and Beta2microglobulin in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Blood (2018) 132 (Supplement 1): 347.

https://doi.org/10.1182/blood-2018-99-118719

Published: 2018

Journal Articles

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Blood (2018) 132 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2018-99-111883

Published: 2018

Journal Articles

Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

Blood (2017) 130 (Supplement 1): 827.

https://doi.org/10.1182/blood.V130.Suppl_1.827.827

Published: 2017

Journal Articles

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Ricardo Sanchez, Mireia Morgades, M.Prob.S, Rosa Ayala, Esther Onecha, Yanira Ruiz-Heredia, Jose M. Sanchez, Susana Vives, MD, Santiago Mercadal, MD, Ramón Guardia, Marta Cervera, MD, Olga García, Jordi Ribera, Josep-Maria Ribera, MD, Joaquín Martínez

Blood (2017) 130 (Supplement 1): 2710.

https://doi.org/10.1182/blood.V130.Suppl_1.2710.2710

Published: 2017

Journal Articles

Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 1559.

https://doi.org/10.1182/blood.V130.Suppl_1.1559.1559

Published: 2017

Journal Articles

Ebv-Mir-BART11-3p, Ebv-Mir-BART9 and Ebv-Mir-BART10 Are Present in the Plasma of HIV-Infected Subjects with Lymphoma and Are Potential Lymphoma Biomarkers

Josep Muncunill, MSc, Maria Joao Baptista, PhD PharmD, Agueda Hernandez-Rodriguez, PhD, Judith Dalmau, PhD, Gustavo Tapia, MD PhD, Olga Garcia, Miriam Moreno, MD, Juan-Manuel Sancho, MD PhD, Javier Martinez-Picado, PhD, Josep-Maria Ribera, MD, Evarist Feliu, MD PhD, Jose-Luis Mate, MD PhD, Jose Tomas Navarro, MD PhD

Blood (2017) 130 (Supplement 1): 4004.

https://doi.org/10.1182/blood.V130.Suppl_1.4004.4004

Published: 2017

Journal Articles

Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain

Blood (2015) 126 (23): 2723.

https://doi.org/10.1182/blood.V126.23.2723.2723

Published: 2015

Journal Articles

Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy

Marc Sorigue, MD, Juan-Manuel Sancho, Santiago Mercadal, MD, Ruben Fernández-Álvarez, MD, Helena Pomares, MD, Olga Garcia, Eva González-Barca, MD PhD, Esther González-García, MD, Miriam Moreno, MD, Cristina Motlló, MD, Montserrat García, MD, Jose-Tomas Navarro, MD PhD, Eva domingo-Domenech, MD, Evarist Feliu, MD PhD, Anna Sureda, MD PhD, Josep-Maria Ribera, MD PhD

Blood (2015) 126 (23): 1510.

https://doi.org/10.1182/blood.V126.23.1510.1510

Published: 2015

Journal Articles

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Blood (2015) 126 (23): 3944.

https://doi.org/10.1182/blood.V126.23.3944.3944

Published: 2015

Journal Articles

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

Maria Joao Baptista, PharmD, PhD, Gustavo Tapia, MD, Ana-Maria Muñoz-Marmol, PhD, Olga Garcia, MD, Josep Muncunill, MSc, Maria-Jose Terol, MD PhD, Eva González-Barca, MD PhD, Pilar Miralles, MD PhD, Ferran Vall-Llovera, MD, Mariano Provencio, MD PhD, Miriam Moreno, MD, Juan-Manuel Sancho, MD PhD, Jose-Luis Mate, MD PhD, Evarist Feliu, MD PhD, Josep-Maria Ribera, MD PhD, Jose-Tomas Navarro, MD PhD

Blood (2015) 126 (23): 3874.

https://doi.org/10.1182/blood.V126.23.3874.3874

Published: 2015

Journal Articles

Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

Blood (2015) 126 (23): 3955.

https://doi.org/10.1182/blood.V126.23.3955.3955

Published: 2015

Journal Articles

Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1

Blood (2014) 124 (21): 1910.

https://doi.org/10.1182/blood.V124.21.1910.1910

Published: 2014

NARROW

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

New Prognosis Score Including Absolute Lymphocytes/Monocytes Ratio and Beta2microglobulin in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization

Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics

Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

Ebv-Mir-BART11-3p, Ebv-Mir-BART9 and Ebv-Mir-BART10 Are Present in the Plasma of HIV-Infected Subjects with Lymphoma and Are Potential Lymphoma Biomarkers

Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain

Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only